14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $21.75 $29.07 Tuesday, 23rd Apr 2024 ARWR stock ended at $23.78. This is 0.585% less than the trading day before Monday, 22nd Apr 2024. During the day the stock fluctuated 4.27% from a day low at $23.67 to a day high of $24.68.
90 days $21.75 $36.72
52 weeks $20.67 $42.48

Historical Arrowhead Research Corporation prices

Date Open High Low Close Volume
Apr 23, 2024 $23.95 $24.68 $23.67 $23.78 803 217
Apr 22, 2024 $22.60 $24.30 $22.24 $23.92 1 053 777
Apr 19, 2024 $22.52 $22.76 $21.75 $22.33 894 002
Apr 18, 2024 $22.42 $22.80 $21.93 $22.61 1 262 282
Apr 17, 2024 $23.88 $23.92 $22.47 $22.53 1 142 887
Apr 16, 2024 $23.73 $24.34 $23.60 $23.67 770 372
Apr 15, 2024 $24.86 $24.86 $23.75 $24.01 853 494
Apr 12, 2024 $25.34 $25.50 $24.47 $24.70 827 362
Apr 11, 2024 $25.74 $25.74 $25.28 $25.68 637 015
Apr 10, 2024 $25.26 $25.48 $24.81 $25.39 875 710
Apr 09, 2024 $25.85 $26.48 $25.63 $26.25 605 777
Apr 08, 2024 $25.96 $26.33 $25.37 $25.70 842 064
Apr 05, 2024 $25.77 $26.43 $25.28 $25.78 693 210
Apr 04, 2024 $26.36 $26.98 $25.85 $26.11 743 145
Apr 03, 2024 $26.00 $26.54 $25.71 $26.48 681 824
Apr 02, 2024 $27.34 $27.42 $25.90 $26.19 1 211 718
Apr 01, 2024 $28.25 $28.50 $27.61 $28.24 598 505
Mar 28, 2024 $28.75 $29.07 $28.10 $28.60 551 391
Mar 27, 2024 $28.21 $28.87 $27.86 $28.70 510 513
Mar 26, 2024 $28.21 $28.45 $27.50 $27.84 674 437
Mar 25, 2024 $27.31 $27.95 $27.31 $27.89 504 157
Mar 22, 2024 $28.16 $28.36 $27.18 $27.21 651 753
Mar 21, 2024 $28.97 $29.93 $28.12 $28.23 1 049 410
Mar 20, 2024 $27.50 $28.36 $27.09 $28.16 895 797
Mar 19, 2024 $28.06 $28.38 $27.54 $27.77 964 428
Click to get the best stock tips daily for free!

About Arrowhead Research Corporation

Arrowhead Research Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in P... ARWR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT